###begin article-title 0
###xml 15 22 15 22 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR2A </italic>
###xml 26 40 26 40 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR2A-FCGR3A </italic>
Association of FCGR2A and FCGR2A-FCGR3A haplotypes with susceptibility to giant cell arteritis
###end article-title 0
###begin p 1
This is an open access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin p 2
###xml 273 278 273 278 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR </italic>
###xml 366 372 366 372 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR2A</italic>
###xml 374 380 374 380 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR3A</italic>
###xml 382 389 382 389 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR3B </italic>
###xml 393 400 393 400 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR2B </italic>
###xml 454 456 454 456 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 503 505 503 505 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 611 612 611 612 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 641 646 641 646 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR </italic>
###xml 767 773 767 773 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR2A</italic>
###xml 859 861 859 861 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 911 917 911 917 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR3A</italic>
###xml 954 956 954 956 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 1020 1025 1020 1025 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR </italic>
###xml 1171 1185 1171 1185 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR2A-FCGR3A </italic>
###xml 1215 1217 1215 1217 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 1344 1350 1344 1350 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR2A</italic>
###xml 1360 1368 1360 1368 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-DRB1</italic>
###xml 1490 1498 1490 1498 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-DRB1</italic>
###xml 1542 1548 1542 1548 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR2A</italic>
###xml 1621 1628 1621 1628 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR2A </italic>
###xml 1646 1654 1646 1654 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-DRB1</italic>
###xml 1694 1701 1694 1701 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR2A </italic>
###xml 1817 1831 1817 1831 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR2A-FCGR3A </italic>
The Fc gamma receptors have been shown to play important roles in the initiation and regulation of many immunological and inflammatory processes and to amplify and refine the immune response to an infection. We have investigated the hypothesis that polymorphism within the FCGR genetic locus is associated with giant cell arteritis (GCA). Biallelic polymorphisms in FCGR2A, FCGR3A, FCGR3B and FCGR2B were examined for association with biopsy-proven GCA (n = 85) and healthy ethnically matched controls (n = 132) in a well-characterised cohort from Lugo, Spain. Haplotype frequencies and linkage disequilibrium (D') were estimated across the FCGR locus and a model-free analysis performed to determine association with GCA. There was a significant association between FCGR2A-131RR homozygosity (odds ratio (OR) 2.10, 95% confidence interval (CI) 1.12 to 3.77, P = 0.02, compared with all others) and carriage of FCGR3A-158F (OR 3.09, 95% CI 1.10 to 8.64, P = 0.03, compared with non-carriers) with susceptibility to GCA. FCGR haplotypes were examined to refine the extent of the association. The haplotype showing the strongest association with GCA susceptibility was the FCGR2A-FCGR3A 131R-158F haplotype (OR 2.84, P = 0.01 for homozygotes compared with all others). There was evidence of a multiplicative joint effect between homozygosity for FCGR2A-131R and HLA-DRB1*04 positivity, consistent with both of these two genetic factors contributing to the risk of disease. The risk of GCA in HLA-DRB1*04 positive individuals homozygous for the FCGR2A-131R allele is increased almost six-fold compared with those with other FCGR2A genotypes who are HLA-DRB1*04 negative. We have demonstrated that FCGR2A may contribute to the 'susceptibility' of GCA in this Spanish population. The increased association observed with a FCGR2A-FCGR3A haplotype suggests the presence of additional genetic polymorphisms in linkage disequilibrium with this haplotype that may contribute to disease susceptibility. These findings may ultimately provide new insights into disease pathogenesis.
###end p 2
###begin title 3
Introduction
###end title 3
###begin p 4
###xml 568 569 568 569 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 736 737 736 737 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 266 274 <span type="species:ncbi:9606">patients</span>
###xml 379 387 <span type="species:ncbi:9606">patients</span>
Giant cell arteritis (GCA) is a common chronic granulomatous vasculitis that is restricted to the over-50 population and thus serves as a paradigm for ageing-related immunopathology. Permanent ischaemic lesions, predominantly irreversible blindness, occur in 15% of patients due to hyperplasia of the intimal layer of involved arteries and non-thrombotic luminal occlusion. Some patients present acutely with blindness, secondary to anterior ischaemic optic neuropathy or central retinal artery occlusion, whereas others present with a systemic inflammatory syndrome [1]. High-dose steroids are conventionally used to prevent these ischaemic complications, but in an elderly population this leads to a high incidence of adverse events [2].
###end p 4
###begin p 5
###xml 320 321 320 321 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 424 436 424 436 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-DRB1*04 </italic>
###xml 467 468 467 468 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 508 520 508 520 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-DRB1*04 </italic>
###xml 568 569 568 569 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 595 596 595 596 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 629 630 629 630 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 850 851 850 851 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 869 870 869 870 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 908 910 908 910 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 949 951 949 951 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 952 954 952 954 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 1030 1032 1030 1032 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 1033 1035 1033 1035 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 1287 1289 1287 1289 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
There is some evidence that GCA is an antigen-driven, autoimmune disease. One of the earliest changes within the vessel wall is the accumulation of dendritic cells within the adventitia, which are believed to initiate and maintain antigen-specific adaptive immune responses, following an as yet unknown vascular insult [3]. The familial clustering of GCA supports a genetic component, and there is a strong association with HLA-DRB1*04 in many different populations [4]. Within cohorts of biopsy-proven GCA, HLA-DRB1*04 is associated with systemic signs and symptoms [5], visual manifestations [6] and corticosteroid resistance [7]. Many other studies have examined genetic variants in key components of immune and inflammatory pathways known to be activated in this disease. Associations with polymorphisms in genes encoding tumour necrosis factor [8], interleukin-4 [9], intracellular adhesion molecule-1 [10], vascular endothelial growth factor [11,12] and endothelial nitric oxide synthase have been reported in some cohorts [13,14], although many are awaiting replication in a second population. Variant alleles of mannose-binding lectin, which result in low levels of mannose-binding lectin protein, are also associated with GCA, perhaps through modulation of phagocytic function [15].
###end p 5
###begin p 6
###xml 164 166 164 166 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 215 235 215 235 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Chlamydia pneumoniae</italic>
###xml 276 278 276 278 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 578 580 578 580 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 980 982 980 982 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 1069 1071 1069 1071 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 1118 1120 1118 1120 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 1407 1409 1403 1405 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 196 210 <span type="species:ncbi:10798">parvovirus B19</span>
###xml 215 235 <span type="species:ncbi:83558">Chlamydia pneumoniae</span>
###xml 920 925 <span type="species:ncbi:9606">human</span>
###xml 1235 1243 <span type="species:ncbi:9606">patients</span>
There is some epidemiological evidence, such as clustering of cases in space and time, that infection may act as a trigger for both GCA and polymyalgia rheumatica [16]. Organisms proposed include parvovirus B19 and Chlamydia pneumoniae, but the evidence remains inconclusive [17]. Infections may lead to vasculitis through various mechanisms: for example, interactions between microbial ligands and endogenous molecules, impairment of pathogen clearance, molecular mimicry, modification of self epitopes into 'neo-antigens', or failure to down-regulate the alloimmune response [18]. The ageing process itself leads to a functional decline in adaptive and innate immune responses, known as immunosenescence, in association with an increased susceptibility to infections, malignancies and autoimmune/inflammatory disorders. Although GCA-specific autoantibodies have not been described, antibodies against a broad range of human autoantigens have been observed in both types of GCA [19]. Anticardiolipin antibodies have been reported, particularly in biopsy-positive GCA [20], and often disappear with steroid treatment [21]. Furthermore, the pathogenicity of anti-endothelial antibodies, which have been demonstrated in up to 50% of GCA patients, remains to be elucidated, but such antibodies have the potential to mediate Fc gamma receptor (FcgammaR) cross-linking and trigger downstream effector functions [22].
###end p 6
###begin p 7
###xml 559 561 531 533 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 562 564 534 536 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 705 707 673 675 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 1042 1044 1002 1004 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 1045 1047 1005 1007 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
The FcgammaRs, which bind IgG containing immune complexes/IgG autoantibodies, have been shown to play important roles in the initiation and regulation of many immunological and inflammatory processes and to amplify and refine the immune response to an infection. Activating FcgammaRs (FcgammaRI, FcgammaRIIa, FcgammaRIIIa, FcgammaRIIIb) potentiate phagocytosis in response to IgG-containing immune complexes/opsonised micro-organisms and trigger the oxidative burst, degranulation, maturation and release of cytokines, including tumour necrosis factor-alpha [23-25]. FcgammaR-mediated endocytosis by antigen presenting cells, such as dendritic cells, results in efficient MHC class I and II presentation [26]. FcgammaRIIIa cross-linking additionally stimulates antigen-dependent cellular cytotoxicity by natural killer cells and macrophages. Conversely, FcgammaRIIb contains an inhibitory motif in the cytoplasmic tail that abrogates cellular activation and down-regulates the antibody response, thus acting as a negative feedback mechanism [23-25]. Polymorphic variants that increase the expression or affinity of these IgG receptors, or enhance their ability to bind specific IgG isotypes, may, therefore, play an important role in determining both the inflammation mediated by IgG (auto)antibodies and IgG-containing immune complexes and/or the susceptibility to specific infections that may be associated with triggering vascular/inflammatory disease.
###end p 7
###begin p 8
###xml 41 46 41 46 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR </italic>
We have examined the hypothesis that the FCGR genetic locus is associated with susceptibility to GCA in a previously well-characterised GCA cohort from north-western Spain.
###end p 8
###begin title 9
Materials and methods
###end title 9
###begin title 10
###xml 21 29 <span type="species:ncbi:9606">patients</span>
Giant cell arteritis patients and controls
###end title 10
###begin p 11
###xml 44 50 44 50 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR2A</italic>
###xml 52 58 52 58 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR3A</italic>
###xml 60 67 60 67 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR3B </italic>
###xml 71 78 71 78 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR2B </italic>
###xml 177 178 177 178 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 179 181 179 181 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 616 618 616 618 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 197 205 <span type="species:ncbi:9606">patients</span>
###xml 393 401 <span type="species:ncbi:9606">patients</span>
###xml 408 416 <span type="species:ncbi:9606">patients</span>
###xml 473 481 <span type="species:ncbi:9606">patients</span>
This was an allelic association study where FCGR2A, FCGR3A, FCGR3B and FCGR2B alleles and pairwise haplotypes were examined in a well-characterised GCA cohort from Lugo, Spain [6,27]. Briefly, all patients and controls were of local Spanish descent and originated from the area surrounding Lugo, Galicia, in north-western Spain. They comprised 217 individuals (132 healthy controls and 85 GCA patients). All patients were recruited from Xeral-Calde Hospital (Lugo) and all patients fulfilled the 1990 American College of Rheumatology criteria for the classification of GCA and had a positive temporal artery biopsy [28]. All controls were healthy volunteers, who could trace their ancestry in the region for at least three generations. Ethical approval was obtained from the respective Local Research Ethics Committees.
###end p 11
###begin title 12
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR </italic>
FCGR genotyping
###end title 12
###begin p 13
###xml 18 23 18 23 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR </italic>
###xml 117 123 117 123 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR2A</italic>
###xml 125 132 125 132 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR2B </italic>
###xml 136 142 136 142 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR2C</italic>
###xml 163 170 163 170 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR3A </italic>
###xml 174 180 174 180 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR3B</italic>
###xml 296 298 296 298 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 367 373 367 373 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR2A</italic>
###xml 382 388 382 388 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR3A</italic>
###xml 400 406 400 406 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR3B</italic>
###xml 456 462 456 462 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR2B</italic>
###xml 585 587 585 587 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 588 590 588 590 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 593 600 593 600 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR2A </italic>
###xml 671 676 671 676 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR </italic>
###xml 737 743 737 743 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR2A</italic>
###xml 745 751 745 751 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR3A</italic>
###xml 753 759 753 759 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR2C</italic>
###xml 761 767 761 767 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR3B</italic>
###xml 769 776 769 776 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR2B </italic>
###xml 777 779 777 779 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 780 782 780 782 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
Genotyping at the FCGR locus is complex in view of the high level of structural homology between the three class II (FCGR2A, FCGR2B and FCGR2C) and two class III (FCGR3A and FCGR3B) receptors. Gene duplication at this locus is believed to have occurred as a result of an unequal crossover event [29] with subsequent divergence of biological functions. The functional FCGR2A-131H/R, FCGR3A-158F/V and FCGR3B-NA1/NA2 polymorphisms and 3' untranslated region FCGR2B-1206G/A single nucleotide polymorphism were genotyped using assays that have previously been validated in our laboratory [30,31]. FCGR2A genotyping was performed by direct sequencing for >80% of samples. The FCGR gene order from centromere to telomere at chromosome 1q23 is FCGR2A, FCGR3A, FCGR2C, FCGR3B, FCGR2B [31,32].
###end p 13
###begin title 14
Statistical analyses
###end title 14
###begin p 15
###xml 249 254 249 254 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR </italic>
###xml 304 306 304 306 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
Statistical analyses were performed using the Stata statistical software (Stata Corporation 2005, Stata Statistical Software: Release 9.0, College Station, Texas, USA) unless otherwise stated. The power calculations for this study were based on the FCGR allele frequencies observed in the UK population [31]. A cohort of 85 GCA cases and 130 controls provides 80% power to detect an odds ratio (OR) of 2.5 or 2.9 for a dominant and recessive mode of inheritance, respectively, assuming an allele frequency of 0.35 (5% significance level); for an allele frequency of 0.5 the corresponding ORs are 3.2 and 2.5). Hardy-Weinberg equilibrium was investigated in each control population using an exact test. Allele and genotype frequencies were compared using 2 x 2 and 3 x 2 contingency tables, respectively. Two-sided P values below 0.05 were considered statistically significant throughout.
###end p 15
###begin p 16
###xml 218 223 218 223 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR </italic>
###xml 284 286 284 286 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 428 429 428 429 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 464 468 464 468 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR</italic>
###xml 753 755 753 755 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
ORs and their 95% confidence intervals (CI) were calculated to quantify the magnitude of all significant associations, as an approximation of the relative risk. Haplotype frequencies were estimated pairwise across the FCGR locus using the Estimating Haplotypes PLUS (EHPLUS) program [33], which also calculates the empirical significance (P value) of overall linkage disequilibrium. The standardised disequilibrium coefficient (D') was calculated for each pair of FCGRs, utilizing the gene order derived from our electronic contig. The heterogeneity test within the Permutation and Model-free analysis program was used to test for association with disease. A permutation procedure implemented in this program enabled 1,000 permutations to be performed [33].
###end p 16
###begin p 17
###xml 15 20 15 20 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR </italic>
###xml 146 148 146 148 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 688 696 688 696 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-DRB1</italic>
###xml 701 703 701 703 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
Association of FCGR haplotypes with GCA was investigated further using the haplotype trend regression approach proposed by Zaykin and colleagues [34] for dealing with uncertain phase. In this method, logistic regression can be used to relate disease status to an individual's haplotypes; where these are not known with certainty all haplotypes consistent with the genotypes are included as predictors, weighted by their probabilities (based on the estimated haplotype frequencies). This approach estimates the effect on risk of each haplotype assuming the effect of the two haplotypes is independent. Stepwise regression analyses were also used to investigate a possible interaction with HLA-DRB1*04 [35].
###end p 17
###begin title 18
Results
###end title 18
###begin title 19
###xml 15 21 15 21 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR2A</italic>
###xml 23 29 23 29 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR3A</italic>
###xml 31 38 31 38 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR3B </italic>
###xml 42 49 42 49 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR2B </italic>
Association of FCGR2A, FCGR3A, FCGR3B and FCGR2B with giant cell arteritis
###end title 19
###begin p 20
There was no evidence of departure from Hardy-Weinberg equilibrium in the control group for any genotyped polymorphism.
###end p 20
###begin p 21
###xml 63 69 63 69 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR2A</italic>
###xml 86 88 86 88 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 111 113 111 113 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 155 156 155 156 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 231 237 231 237 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR2A</italic>
###xml 310 312 310 312 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 397 403 397 403 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR3A</italic>
###xml 419 421 419 421 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 443 445 443 445 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 509 510 509 510 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 580 586 580 586 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR3A</italic>
###xml 654 656 654 656 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 706 713 706 713 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR3B </italic>
###xml 716 723 716 723 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR2B </italic>
###xml 472 480 <span type="species:ncbi:9606">patients</span>
There was weak evidence of a difference in the distribution of FCGR2A-131H/R alleles (P = 0.05) and genotypes (P = 0.06) between cases and controls (Table 1). The data supported a recessive model and individuals homozygous for the FCGR2A-131R allele had an increased risk of GCA (OR 2.10, 95% CI 1.12 to 3.77, P = 0.02, compared with all others). There was also a trend towards an increase in the FCGR3A-158F/V allele (P = 0.06) and genotype (P = 0.08) frequencies in GCA patients compared to controls (Table 1). The data were consistent with a dominant model and carriage of the FCGR3A-158F allele was associated with GCA (OR 3.09, 95% CI 1.10 to 8.64, P = 0.03). There were no significant differences in FCGR3B or FCGR2B allele or genotype frequencies between GCA subjects and controls.
###end p 21
###begin title 22
###xml 30 35 30 35 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR </italic>
Linkage disequilibrium at the FCGR genetic locus
###end title 22
###begin p 23
###xml 56 63 56 63 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR2A </italic>
###xml 67 74 67 74 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR3A </italic>
###xml 75 78 75 78 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D' </italic>
###xml 86 88 86 88 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 100 107 100 107 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR3A </italic>
###xml 111 118 111 118 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR3B </italic>
###xml 119 122 119 122 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D' </italic>
###xml 131 133 131 133 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 183 186 183 186 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D' </italic>
###xml 320 321 320 321 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
Significant linkage disequilibrium was observed between FCGR2A and FCGR3A (D' = 0.31, P = 0.01) and FCGR3A and FCGR3B (D' = -0.64, P = 0.0001) in the control population. The negative D' values indicate linkage disequilibrium between the commonest allele of one gene and the least common allele of the second gene (Table 2).
###end p 23
###begin title 24
###xml 15 20 15 20 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR </italic>
Association of FCGR haplotypes with giant cell arteritis
###end title 24
###begin p 25
###xml 31 36 31 36 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR </italic>
###xml 161 175 161 175 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR2A-FCGR3A </italic>
###xml 182 183 182 183 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
###xml 234 248 234 248 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR2A-FCGR3A </italic>
###xml 308 316 <span type="species:ncbi:9606">patients</span>
The distributions of two-locus FCGR haplotypes were compared between the GCA and control populations, with a difference approaching statistical significance for FCGR2A-FCGR3A (Table 3). Compared with the control frequency of 36%, the FCGR2A-FCGR3A 131R-158F haplotype was found at increased frequency in GCA patients (50%).
###end p 25
###begin p 26
###xml 48 62 48 62 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR2A-FCGR3A </italic>
###xml 187 189 187 189 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 566 580 566 580 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR2A-FCGR3A </italic>
###xml 781 783 781 783 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
From the haplotype trend regression analysis of FCGR2A-FCGR3A haplotypes, the 131R-158F haplotype was found to have a significant effect on the risk of GCA (OR 1.72, 95% CI 1.02 to 2.89, P = 0.04), compared to the H-V haplotype as baseline. These are maximum likelihood estimates of the effect of each haplotype assuming a log-additive combined effect of an individual's two haplotypes. Further analysis treating the number of copies of this haplotype as a factor shows that the effect of the haplotype is largely confined to those with two copies (data not shown). FCGR2A-FCGR3A haplotypes were analysed under a recessive model, where homozygosity for this haplotype was observed in 12% healthy controls compared with 27% GCA population giving an OR of 2.84, 95% CI 1.33 to 6.06 (P = 0.01) when homozygotes were compared with all others.
###end p 26
###begin title 27
###xml 16 23 16 23 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR2A </italic>
###xml 36 44 36 44 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-DRB1</italic>
Contribution of FCGR2A genotype and HLA-DRB1*04 alleles in giant cell arteritis susceptibility
###end title 27
###begin p 28
###xml 77 83 77 83 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR2A</italic>
###xml 93 101 93 101 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-DRB1</italic>
###xml 347 355 347 355 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-DRB1</italic>
###xml 399 405 399 405 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR2A</italic>
###xml 478 485 478 485 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR2A </italic>
###xml 503 511 503 511 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-DRB1</italic>
###xml 596 598 596 598 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
There was evidence of a multiplicative joint effect between homozygosity for FCGR2A-131R and HLA-DRB1*04 positivity, consistent with both of these two genetic factors contributing to the risk of disease (OR 2.23, 95% CI 1.09 to 4.58 and OR 2.61, 95% CI 1.30 to 5.22, respectively, from a model including both predictors). Thus, the risk of GCA in HLA-DRB1*04 positive individuals homozygous for the FCGR2A-131R allele is increased almost six-fold compared with those with other FCGR2A genotypes who are HLA-DRB1*04 negative. There is no evidence of an interaction between these two genetic loci (P = 0.19 from a likelihood ratio test).
###end p 28
###begin title 29
Discussion
###end title 29
###begin p 30
###xml 55 61 55 61 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR2A</italic>
###xml 77 79 77 79 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 91 97 91 97 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR3A</italic>
###xml 113 115 113 115 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 451 453 451 453 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 490 504 490 504 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR2A-FCGR3A </italic>
###xml 597 599 597 599 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
We have demonstrated a significant association between FCGR2A-131RR (OR 2.1, P = 0.02) and FCGR3A-158F (OR 3.09, P = 0.03) with susceptibility to GCA. Haplotype analyses can be more informative in their ability to identify disease predisposing genes. They may also provide additional evidence for the presence of unidentified polymorphic variants that are in linkage disequilibrium with the haplotype and are the true disease-susceptibility variants [36]. Accordingly, homozygosity for the FCGR2A-FCGR3A 131R-158F haplotype was associated with an almost three-fold increased risk of GCA (OR 2.84, P = 0.01).
###end p 30
###begin p 31
###xml 148 154 144 150 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR2A</italic>
###xml 164 170 160 166 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR3A</italic>
###xml 559 565 535 541 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR2A</italic>
###xml 781 803 757 779 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Neisseria meningitides</italic>
###xml 805 828 781 804 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Haemophilus influenzae </italic>
###xml 832 857 808 833 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Streptococcus pneumoniae </italic>
###xml 858 860 834 836 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 861 863 837 839 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
###xml 1466 1468 1406 1408 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 346 352 <span type="species:ncbi:9606">humans</span>
###xml 805 827 <span type="species:ncbi:727">Haemophilus influenzae</span>
###xml 832 856 <span type="species:ncbi:1313">Streptococcus pneumoniae</span>
The FcgammaRs play important roles in the initiation and propagation of many different immunological and inflammatory processes. The two alloforms (FCGR2A-131R and FCGR3A-158F) contained within the GCA-susceptibility haplotype encode low affinity variants (FcgammaRIIa-131R and FcgammaRIIIa-158F). FcgammaRIIa is the major phagocytic FcgammaR in humans and has two co-dominantly expressed alleles, 131H and 131R. The 131H isoform is the only FcgammaR that can bind IgG2, an antibody subclass that is also a poor activator of the classical complement pathway. FCGR2A-131H is, therefore, essential for handling IgG2 immune complexes: individuals homozygous for the 131R-allele have been shown to have an increased susceptibility to various encapsulated bacterial infections, such as Neisseria meningitides, Haemophilus influenzae and Streptococcus pneumoniae [37-39]. FcgammaRIIIa is expressed on natural killer cells, macrophages, gammadelta T-cells and a subset of monocytes. Consequently, they may act as susceptibility factors for GCA through a variety of mechanisms, such as an inability to bind IgG2 haplotypes (FcgammaRIIa-131R) on a background of impaired FcgammaR-mediated phagocytosis (FcgammaRIIa-131R and FcgammaRIIIa-158F) and impaired antigen-dependent cellular cytotoxicity of IgG-opsonised cells (FcgammaRIIIa-158F). Alternatively, FcgammaR polymorphisms may modulate endothelial leukocyte ingress, dendritic cell endocytosis and antigen presentation [26], or macrophage/natural killer cell effector functions to IgG containing immune complexes, each of which could separately influence the pathogenesis of GCA.
###end p 31
###begin p 32
###xml 202 209 202 209 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGRIIA</italic>
###xml 216 224 216 224 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGRIIIA</italic>
###xml 234 242 234 242 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGRIIIB</italic>
###xml 321 328 321 328 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGRIIA</italic>
###xml 338 346 338 346 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGRIIIA</italic>
###xml 361 363 361 363 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B40">40</xref>
###xml 494 516 494 516 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Staphylococcus aureus </italic>
###xml 494 515 <span type="species:ncbi:1280">Staphylococcus aureus</span>
The same polymorphic variants have also been demonstrated to be associated with susceptibility to a variety of autoimmune diseases. For example, systemic lupus erythematosus is associated with the same FCGRIIA-131R, FCGRIIIA-158F and FCGRIIIB-NA2 alleles, whereas relapses in Wegener's granulomatosis are associated with FCGRIIA-131R and FCGRIIIA-158F alleles [40]. Flares in both systemic lupus erythematosus and Wegener's may be triggered by infection, particularly chronic nasal carriage of Staphylococcus aureus in the latter, but the picture is also complicated by impaired FcgammaR-mediated clearance of pathogenic autoantibodies and immune complexes.
###end p 32
###begin title 33
Conclusion
###end title 33
###begin p 34
###xml 32 37 32 37 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR </italic>
Genetic polymorphism within the FCGR genetic locus may contribute to the development of GCA. The immunological consequences of these subtle defects in the innate immune system may be enhanced in the presence of immunosenescence, and the increased susceptibility to infection may potentially allow triggering of the inflammatory process in GCA. Additional studies from other ethnic groups will be required to confirm these genetic associations.
###end p 34
###begin title 35
Abbreviations
###end title 35
###begin p 36
CI = confidence interval; FcgammaR = Fc gamma receptor; GCA = giant cell arteritis; NA = neutrophil antigen; OR = odds ratio.
###end p 36
###begin title 37
Competing interests
###end title 37
###begin p 38
The authors declare that they have no competing interests.
###end p 38
###begin title 39
Authors' contributions
###end title 39
###begin p 40
###xml 359 367 <span type="species:ncbi:9606">patients</span>
AWM participated in the design of the study, oversaw all aspects of the laboratory work, analysed the data and prepared the manuscript. JIR, AW and SJB undertook the genotyping assays on DNA prepared in the laboratory of WERO and JHB provided additional statistical support. MAG-G and JM participated in the collection of clinical data and the recruitment of patients into this study. WERO and JDI participated in the design of the study, interpretation of the results and writing of the final manuscript.
###end p 40
###begin title 41
Acknowledgements
###end title 41
###begin p 42
This work was supported by a grant from The Health Foundation and Dr Ann Morgan is currently funded by the Arthritis Research Campaign, UK.
###end p 42
###begin article-title 43
###xml 83 91 <span type="species:ncbi:9606">patients</span>
Giant cell arteritis: disease patterns of clinical presentation in a series of 240 patients
###end article-title 43
###begin article-title 44
###xml 102 110 <span type="species:ncbi:9606">patients</span>
Analysis of steroid related complications and mortality in temporal arteritis: a 15-year survey of 43 patients
###end article-title 44
###begin article-title 45
Activation of arterial wall dendritic cells and breakdown of self-tolerance in giant cell arteritis
###end article-title 45
###begin article-title 46
Genetic markers of disease susceptibility and severity in giant cell arteritis and polymyalgia rheumatica
###end article-title 46
###begin article-title 47
HLA-DRB1 alleles associated with polymyalgia rheumatica in northern Italy: correlation with disease severity
###end article-title 47
###begin article-title 48
###xml 83 91 <span type="species:ncbi:9606">patients</span>
Visual manifestations of giant cell arteritis. Trends and clinical spectrum in 161 patients
###end article-title 48
###begin article-title 49
Relation between HLA DRB1 alleles and corticosteroid resistance in giant cell arteritis
###end article-title 49
###begin article-title 50
Association of giant cell arteritis and polymyalgia rheumatica with different tumor necrosis factor microsatellite polymorphisms
###end article-title 50
###begin article-title 51
Epistatic interactions between HLA-DRB1 and interleukin 4, but not interferon-gamma, increase susceptibility to giant cell arteritis
###end article-title 51
###begin article-title 52
Intercellular adhesion molecule 1 gene polymorphisms in polymyalgia rheumatica/giant cell arteritis: association with disease risk and severity
###end article-title 52
###begin article-title 53
Vascular endothelial growth factor gene polymorphisms in giant cell arteritis
###end article-title 53
###begin article-title 54
A functional variant of vascular endothelial growth factor is associated with severe ischemic complications in giant cell arteritis
###end article-title 54
###begin article-title 55
Endothelial nitric oxide synthase gene polymorphisms in giant cell arteritis
###end article-title 55
###begin article-title 56
Endothelial nitric oxide synthase haplotype associations in biopsy-proven giant cell arteritis
###end article-title 56
###begin article-title 57
Mannose-binding lectin variant alleles and HLA-DR4 alleles are associated with giant cell arteritis
###end article-title 57
###begin article-title 58
The incidence of giant cell arteritis in Olmsted County, Minnesota - apparent fluctuations in a cyclic pattern
###end article-title 58
###begin article-title 59
Large-vessel vasculitis
###end article-title 59
###begin article-title 60
Large-vessel vasculitis. Unresolved issues
###end article-title 60
###begin article-title 61
###xml 58 66 <span type="species:ncbi:9606">patients</span>
Analysis of the B cell repertoire against autoantigens in patients with giant cell arteritis and polymyalgia rheumatica
###end article-title 61
###begin article-title 62
Anticardiolipin antibodies and giant cell arteritis
###end article-title 62
###begin article-title 63
Anticardiolipin antibodies in giant cell arteritis and polymyalgia rheumatica: a study of 40 cases
###end article-title 63
###begin article-title 64
Classification of anti-endothelial cell antibodies into antibodies against microvascular and macrovascular endothelial cells: the pathogenic and diagnostic implications
###end article-title 64
###begin article-title 65
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human receptors for immunoglobulin G: key elements in the pathogenesis of rheumatic disease
###end article-title 65
###begin article-title 66
IgG Fc Receptors
###end article-title 66
###begin article-title 67
Roles of Fc receptors in autoimmunity
###end article-title 67
###begin article-title 68
Fcg receptor-mediated induction of dendritic cell maturation and major histocompatibility complex class I-restricted antigen presentation after immune complex internalisation
###end article-title 68
###begin article-title 69
The spectrum of polymyalgia rheumatica in northwestern Spain: incidence and analysis of variables associated with relapse in a 10 year study
###end article-title 69
###begin article-title 70
The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis
###end article-title 70
###begin article-title 71
###xml 4 9 <span type="species:ncbi:9606">human</span>
The human low affinity immunoglobulin G Fc receptor IIC gene is a result of an unequal cross-over event
###end article-title 71
###begin article-title 72
FcgRIIIA-158V and rheumatoid arthritis. A confirmation study
###end article-title 72
###begin article-title 73
###xml 61 68 61 68 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR3A </italic>
###xml 155 161 155 161 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR3B</italic>
Analysis of Fcg receptor haplotypes in rheumatoid arthritis. FCGR3A remains a major susceptibility gene at this locus with an additional contribution from FCGR3B
###end article-title 73
###begin article-title 74
###xml 34 39 <span type="species:ncbi:9606">human</span>
Genomic organization of classical human low-affinity Fcgamma receptor genes
###end article-title 74
###begin article-title 75
Model-free analysis and permutation tests for allelic associations
###end article-title 75
###begin article-title 76
Testing association of statistically inferred haplotypes with discrete and continuous traits in samples of unrelated individuals
###end article-title 76
###begin article-title 77
###xml 157 161 157 161 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA </italic>
A unified stepwise regression procedure for evaluating the relative effects of polymorphisms within a gene using case/control or family data: application to HLA in Type 1 diabetes
###end article-title 77
###begin article-title 78
Genetic analysis of case/control data using estimated haplotype frequencies: application to APOE locus variation and Alzheimer's disease
###end article-title 78
###begin article-title 79
Polymorphism of IgG Fc receptors in meningococcal disease
###end article-title 79
###begin article-title 80
###xml 68 90 <span type="species:ncbi:727">Haemophilus influenzae</span>
Global genetic structure and molecular epidemiology of encapsulated Haemophilus influenzae
###end article-title 80
###begin article-title 81
Associations between Fc gamma receptor IIA polymorphisms and the risk and prognosis of meningococcal disease
###end article-title 81
###begin article-title 82
Fcg receptor polymorphisms in Wegener's granulomatosis: risk factors for disease relapse
###end article-title 82
###begin title 83
Figures and Tables
###end title 83
###begin p 84
Genotype frequencies (number and proportion) in subjects with giant cell arteritis compared to controls
###end p 84
###begin p 85
GCA, giant cell arteritis.
###end p 85
###begin p 86
###xml 42 44 42 44 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D'</italic>
Pairwise linkage disequilibrium measures (D') calculated from the control group
###end p 86
###begin p 87
Values of 0.3 and higher highlighted in bold.
###end p 87
###begin p 88
Estimated pairwise haplotype frequencies in giant cell arteritis compared with healthy controls
###end p 88
###begin p 89
###xml 58 64 58 64 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR2A</italic>
###xml 73 79 73 79 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR3A</italic>
###xml 88 94 88 94 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR3B</italic>
###xml 105 111 105 111 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR2B</italic>
###xml 160 165 160 165 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR </italic>
###xml 221 227 221 227 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR2A</italic>
###xml 237 243 237 243 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FCGR3A</italic>
###xml 268 270 268 270 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
Pairwise haplotypes produced from four biallelic markers (FCGR2A-131H/R, FCGR3A-158F/V, FCGR3B-NA2/1 and FCGR2B-1206G/A) denoted in the order they occur at the FCGR locus. Thus, 131R-158F indicates a haplotype containing FCGR2A-131R and FCGR3A-158F alleles. Empirical P values were obtained from a heterogeneity test statistic incorporated in the Permutation and Model-free analysis program after 1,000 permutations.
###end p 89

